Contact
QR code for the current URL

Story Box-ID: 344578

Agennix AG Landsbergerstrasse 302 80687 München, Germany http://www.agennix.com
Contact +49 89 85652693
Company logo of Agennix AG
Agennix AG

Agennix AG kündigt die Präsentation von Daten der Phase-2-Studie mit Talactoferrin bei schwerer Blutvergiftung auf der American Thoracic Society International Conference am 17. Mai an

(PresseBox) (Martinsried/München und US-Standorte in Princeton, NJ, und Houston, TX, )
Agennix AG (Deutsche Börse: AGX) gab heute bekannt, dass Daten der Phase-2-Studie mit Talactoferrin zur Behandlung von schwerer Blutvergiftung (Sepsis) auf der "American Thoracic Society International Conference (ATS)" in New Orleans, LA, vorgestellt werden. Die Präsentation "Talactoferrin Alfa Reduces Mortality in Severe Sepsis: Results of a Phase 2 Randomized, Placebo-Controlled Double-Blind Study" ist Teil des Mini-Symposiums "New Treatment Approaches for Lung Disease: Late Breaking Abstracts". Die Daten werden am Montag, 17. Mai 2010 um 9:45 Uhr Ortszeit (16:45 Uhr MESZ) von der leitenden Prüfärztin der Talactoferrin-Studie, Dr. K. Guntupalli, Professor & Chief, Pulmonary Critical Care and Sleep Medicine am Baylor
Sqpruko rj Fdctwifh, tvtflvzptzz.
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2026, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.